Unicycive Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Unicycive resubmitted its NDA for oxylanthanum carbonate on September 29, 2026, adding a new third-party drug product manufacturing vendor with FDA-approved facility status (No Action Indicated inspection, March 2024) and 12 months of stability data. The company expects FDA acceptance within 30 days and a new PDUFA date 6 months from resubmission. Cash position of $61.4M (as of June 30, 2026) supports runway into 2H 2027; the original vendor remains under FDA inspection assignment but uninspected as of filing date.
Why this rating
NDA resubmission with credible manufacturing solution is material progression for pre-approval biotech (OLC is lead asset). $61.4M cash runway supports execution. Approval odds remain uncertain; manufacturing path now de-risked but regulatory timeline still dependent on FDA actions and original vendor reinspection outcome. Meaningful for $64M market-cap company.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-12.3% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.97 ▲ 8.28% | at our read · unknown $4.59 | +10 min · unknown $4.43 ▼ 3.38% | +30 min pending | +1 hr pending | +4 hrs pending |
The stock had already moved -7.65% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.